MedPath

SANOFI PASTEUR

SANOFI PASTEUR logo
🇫🇷France
Ownership
Subsidiary
Established
1990-01-01
Employees
10K
Market Cap
-
Website
http://www.sanofipasteur.com

Clinical Trials

423

Active:67
Completed:329

Trial Phases

5 Phases

Phase 1:86
Phase 2:81
Phase 3:143
+2 more phases

Drug Approvals

34

SFDA:17
NMPA:8
PHILIPPINES:7
+2 more agencies

Drug Approvals

Haemophilus Type b Conjugate Vaccine

Product Name
安尔宝
Approval Number
国药准字J20140173
Approval Date
May 25, 2020
NMPA

Haemophilus Type b Conjugate Vaccine

Product Name
安尔宝
Approval Number
S20140013
Approval Date
Apr 12, 2020
NMPA

Haemophilus Type b Conjugate Vaccine

Product Name
安尔宝
Approval Number
S20140014
Approval Date
Apr 12, 2020
NMPA

POLIOMYELITIS VACCINE (INACTIVATED)

Product Name
爱宝惟
Approval Number
国药准字J20140171
Approval Date
Sep 16, 2019
NMPA

POLIOMYELITIS VACCINE (INACTIVATED)

Product Name
爱宝惟
Approval Number
S20140062
Approval Date
Aug 8, 2019
NMPA

POLIOMYELITIS VACCINE (INACTIVATED)

Product Name
爱宝惟
Approval Number
S20140063
Approval Date
Aug 8, 2019
NMPA

Clinical Trials

Distribution across different clinical trial phases (374 trials with phase data)• Click on a phase to view related trials

Phase 3
143 (38.2%)
Phase 1
86 (23.0%)
Phase 2
81 (21.7%)
Phase 4
62 (16.6%)
Not Applicable
2 (0.5%)

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

Phase 1
Recruiting
Conditions
Acne
Interventions
First Posted Date
2025-06-10
Last Posted Date
2025-07-10
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
120
Registration Number
NCT07013747
Locations
🇺🇸

Encino Research Center- Site Number : 8400008, Encino, California, United States

🇺🇸

DelRicht Research- Site Number : 8400003, New Orleans, Louisiana, United States

Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

Recruiting
Conditions
Hepatitis B
Haemophilus Influenzae Type b Immunisation
Interventions
Biological: DTaP-IPV-Hep B-PRP-T combined vaccine
First Posted Date
2025-03-25
Last Posted Date
2025-03-25
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
690
Registration Number
NCT06793826
Locations
🇰🇷

Investigational Site Number : 002, Cheonan, Korea, Republic of

🇰🇷

Investigational Site Number : 001, Seoul, Korea, Republic of

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

Phase 3
Recruiting
Conditions
Pneumococcal Infections
Interventions
Biological: 20vPCV
First Posted Date
2025-02-20
Last Posted Date
2025-03-20
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
1252
Registration Number
NCT06838000
Locations
🇺🇸

Site #8400010, Binghamton, New York, United States

Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants

Active, not recruiting
Conditions
Respiratory Syncytial Virus Immunization
First Posted Date
2025-02-13
Last Posted Date
2025-06-05
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
2400
Registration Number
NCT06824207

Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants

Active, not recruiting
Conditions
Influenza Immunization
First Posted Date
2025-01-30
Last Posted Date
2025-06-26
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
5000
Registration Number
NCT06800885
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 75
  • Next

News

Saint Louis University Launches Phase 1 Trial for Investigational West Nile Virus Vaccine

Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.